A Six-month Non-interventional Prospective Study of Various Controller Therapies for Moderate Persistent and Severe Persistent Asthma in Children in Real Life Outpatient Clinical Practice

AstraZeneca1 site in 1 country283 target enrollmentApril 2011

ConditionsAsthma

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Asthma
Sponsor: AstraZeneca
Enrollment: 283
Locations: 1
Primary Endpoint: To compare percentage (%) of responding children by the end of 6-month observation. Responders are defined as children with adequate control of symptoms at the end of 6 months observation (Childhood Asthma Control Test (CACT) score > 19)
Status: Completed
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a six-month non-interventional prospective study of various controller therapies in children with asthma in outpatient clinical practice.

Registry

clinicaltrials.gov

Start Date

April 2011

End Date

October 2012

Last Updated

13 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

AstraZeneca

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Child (male or female) aged 5 to 11 years inclusive
•Provision of Subject Informed Consent Form for anonymous data collection and their subsequent use (must be signed by any of the parents)
•The child must be included in an out-patient observation program at a medical institution for established bronchial asthma diagnosis for at least 1 year prior to enrolment and diagnosed with moderate to severe bronchial asthma at the time of enrolment
•The child must have at least one documented bronchial asthma exacerbation in previous 1 year (including hospital admissions for bronchial asthma exacerbations, any cases of daytime hospital treatment without overnight stays and any cases of oral administration of glucocorticoids on an out-patient basis for \> 3 consecutive days)
•Out-patient receiving step 3 controller treatments with fixed dose combinations of ICSs and LABA or treatment with separate administration of glucocorticoids and LABA in stable doses with adequate control of bronchial asthma symptoms
•The patient administered with short-acting β2 agonists (inhalational) or rapidly released methylxanthines (oral) in the doses approved for the respective age as a rescue on-demand therapies during the preceding month

Exclusion Criteria

•Cystic fibrosis, α1-antitrypsin deficiency or congenital abnormalities of lung development
•Severe comorbidities affecting the patient's overall performance
•In the physician's opinion, the patient is not able to comply with the protocol requirements
•Expected specific hyposensibilization within next 6 months
•Expected treatment at health resort facilities within next 6 months
•Other reasons that in the physician's opinion will prevent reliable assessments of the study treatment efficacy

Outcomes

Primary Outcomes

To compare percentage (%) of responding children by the end of 6-month observation. Responders are defined as children with adequate control of symptoms at the end of 6 months observation (Childhood Asthma Control Test (CACT) score > 19)

Time Frame: 3 visits for 6 month

Secondary Outcomes

To determine mean number of severe bronchial asthma exacerbations within 6 months(3 visits for 6 month)
To determine mean duration of bronchial asthma exacerbations including hospital admissions, daytime hospital treatment and any cases of oral administration of glucocorticoids > 3 consecutive days during the observation period(3 visits for 6 month)
To determine mean requirement in short-acting β2-agonists and/or rapidly released methylxanthines per week during the period of observation(3 visits for 6 month)
To determine the independent factors associated with failure of treatment of asthma (demographic and baseline patient data, site)(3 visits for 6 month)